Prescribing overview
Vetoryl suppresses adrenal hormone production; ongoing laboratory assessment is integral to treatment.
Key prescribing checks
- Do not use in pregnant dogs, dogs with primary hepatic disease or renal insufficiency, or patients with hypersensitivity to trilostane, as described in the label.
- Excess adrenal suppression can produce hypoadrenocorticism, electrolyte disturbances and collapse. Vomiting, diarrhea, weakness or appetite loss warrants prompt assessment.
- Laboratory monitoring and clinical reassessment are integral to treatment, including after changes. Improved outward signs do not remove the need for monitoring.
- Review concurrent drugs affecting potassium or adrenal function and the full client information sheet before dispensing.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US FDA-approved Vetoryl capsulesPituitary-dependent or adrenal-dependent hyperadrenocorticism
Contraindicated with pregnancy, primary hepatic disease, renal insufficiency or trilostane hypersensitivity.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Inhibits adrenal steroid synthesis through 3-beta-hydroxysteroid dehydrogenase inhibition.
Absorption, distribution, metabolism and elimination
Food enhances canine absorption. Healthy-dog peaks occur within 1.5 hours, with large individual variation; levels return to baseline within twelve hours.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Vetoryl
Oral capsule; Dogs
Contraindications · when not to use
- Trilostane hypersensitivity; primary hepatic disease; renal insufficiency; pregnancy.
Precautions & monitoring
- Hypoadrenocorticism may be prolonged or permanent; stop and contact veterinarian for toxicity signs. Lactating/breeding-male safety untested.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Poor appetite, vomiting, diarrhea and weakness; adrenal necrosis/rupture and prolonged or permanent hypoadrenocorticism may occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| DogsHyperadrenocorticismVetoryl capsules | Starting 2.2–6.7 mg/kg; choose lowest possible available capsule combination Oral · Once daily with food Initial treatment until reassessment at 10–14 days; ongoing individualized therapy | Veterinarian adjusts using clinical findings and adrenal testing. Do not open/split capsules. Verify full dosing label ↗ |
Do not combine with potassium-sparing diuretics; review ACE inhibitors and previous mitotane.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Vetoryl
Oral capsule; Dogs
- Do not combine with potassium-sparing diuretics; use caution with ACE inhibitors. Prior mitotane requires adrenal recovery assessment.
Monitoring
At 10–14 days: examination, ACTH stimulation 4–6 hours after dosing, electrolytes and renal/hepatic chemistry; repeat after adjustments and routinely.
Client counseling
Stop and contact the veterinarian promptly for anorexia, vomiting, diarrhea, weakness or collapse.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store at 25°C, excursions 15–30°C. Pregnant people should avoid handling.
Brands, formulations & ingredient identity
Active ingredients
Trilostane
Vetoryl capsules contain trilostane; this drug suppresses hormone production and is not a steroid replacement product.
Capsule strength, formulation and the prescribed administration plan need checking. Compounded products are not automatically equivalent to this approved brand.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Vetoryl
- Formulation
- Oral capsule
- Label / product scope
- Dogs
Trilostane product for canine hyperadrenocorticism.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →